Archer Materials (ASX:AXE) Share Price Holds Focus on Quantum Partnership and Technology Programs

Anjali Anand

19 August 2026 10:23 PM AEST

Archer Materials (ASX:AXE) Share Price Holds Focus on Quantum Partnership and Technology Programs

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Archer Materials Limited (ASX:AXE) shares closed at AUD 0.225 on 19 August 2026, unchanged during the session.
The company continues progressing its quantum technology strategy through a strategic agreement with IonQ.
Archer raised approximately AUD 7.95 million through Placement and share purchase plan activities.
The company is developing Quantum Computing and biochip technology programs.
Revenue generation remains at a development stage, with future progress dependent on commercialisation milestones.

Archer Materials Limited (ASX:AXE) shares closed at AUD 0.225 on 19 August 2026, unchanged compared with the previous close. The stock traded between AUD 0.225 and AUD 0.240 during the session, with a Volume of 73,942 shares.

The company recorded a Market Capitalisation of AUD 63.85 million, with 283,785,249 ordinary fully paid shares on issue.

The share price remained below the AUD 0.270 price at which the company completed its recent capital raising activities. Trading activity followed several technology-related updates, including developments across quantum computing and biochip programs.

Business Overview and Technology Programs

Archer Materials is a technology company focused on semiconductor devices, quantum technology and medical diagnostic applications.

The company is developing two main programs. The first is a quantum technology program focused on quantum computing applications and semiconductor devices. The second is a biochip program focused on developing a point-of-care biosensor designed to measure blood potassium levels from small samples.

Archer remains a pre-revenue company and is funded through Equity raisings, research grants and available development programs.

IonQ Partnership and Quantum Computing Strategy

In July 2026, Archer announced a strategic agreement with IonQ to advance quantum computing opportunities in Australia. Under the agreement, Archer receives access to IonQ’s Quantum Cloud, quantum simulator and advisory services to support application development.

The agreement includes an initial three-year term, with Archer making payments of US$250,000 on signing and US$250,000 every six months, representing approximately US$1.5 million over the agreement period.

The companies are also assessing the potential deployment of an IonQ quantum computer in Australia, including evaluating suitable infrastructure and engaging potential customers across corporate, government, research and education sectors.

The partnership is intended to support Archer’s quantum application development, including work related to quantum machine learning.

Capital Raising and Funding Position

Archer completed a capital raising program during July and August 2026 to support its technology initiatives.

The company completed a AUD 7 million placement, with AUD 6.86 million raised through the first tranche. A further AUD 953,000 was raised through the share purchase plan, bringing total funds raised to approximately AUD 7.95 million.

The funds are being used to support implementation of the IonQ agreement, sovereign quantum initiatives, technology development programs and Working Capital requirements.

The recent raising increased available funding but also resulted in additional shares being issued.

Biochip Development Progress

Alongside quantum technology activities, Archer continues advancing its biochip program.

In July 2026, the company reported progress towards clinical-ready device development. A subsequent update in August 2026 covered an early pre-pilot blood collection study involving 20 donors.

The study evaluated a capillary collection method and assessed haemolysis levels compared with conventional blood collection methods. Archer stated that the work was intended to support future prototype development and planned regulatory engagement rather than represent clinical validation.

Financial Position and Key Metrics

Based on the 19 August 2026 market data, Archer had a market capitalisation of AUD 63.85 million. The company does not currently generate product Revenue and does not have a meaningful price-to-earnings ratio.

Trailing diluted Earnings per share remained negative at approximately AUD 0.02, reflecting the company’s development-stage operating profile.

The upcoming quarterly reporting cycle will provide further information on cash usage following the recent capital raising and progress across technology programs.

Key Areas to Monitor

Future updates will focus on progress under the IonQ partnership, potential customer engagement, quantum application development and the company’s broader commercialisation pathway.

The biochip program will also remain an area of focus, particularly progress towards prototype development and future regulatory discussions.

Investors will continue monitoring cash requirements, development timelines and the company’s ability to convert technology programs into commercial opportunities.

Risks and Challenges

Archer Materials faces risks related to commercialisation timelines, funding requirements, technology development, regulatory approvals and customer adoption. The company remains pre-revenue, and the IonQ agreement creates ongoing payment commitments before commercial revenue is established. Biochip development also involves regulatory uncertainty, while quantum technology remains an emerging market requiring further customer adoption.

Outlook

Archer Materials continues to advance its quantum and biochip programs through partnerships, technology development and research activities. The IonQ agreement provides access to quantum computing infrastructure while the company continues developing its own technology capabilities. Future progress will depend on customer adoption, prototype development, regulatory engagement and the company’s ability to establish commercial applications for its technology platforms.

Conclusion

Archer Materials’ share price remained unchanged on 19 August 2026 as the company continued progressing its quantum computing and biochip development programs. The company has strengthened its funding position through recent capital raising activities and entered a strategic quantum partnership to support application development. However, Archer remains at a development stage, with future performance dependent on technology milestones, commercial adoption and funding requirements.

FAQs

Q: What does Archer Materials Limited (ASX:AXE) do?

A:Archer Materials develops semiconductor-based technology programs, including quantum computing devices and biochip applications.

Q: What was Archer Materials’ share price on 19 August 2026?

A:Archer Materials shares closed at AUD 0.225 on 19 August 2026, unchanged from the previous close.

Q: What is the IonQ agreement?

A:The IonQ agreement provides Archer access to quantum computing infrastructure, cloud services and technical support while both companies assess potential quantum deployment opportunities in Australia.

Q: How much capital did Archer Materials raise in 2026?

A:Archer raised approximately AUD 7.95 million through a placement and share purchase plan during July and August 2026.

Q: What are Archer Materials’ main risks?

A:Key risks include commercialisation timelines, funding requirements, technology development, regulatory approvals and customer adoption.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.